MedWatch

Lundbeck has halted studies in Russia, continues to supply medicine

Like many other pharmaceutical firms recently, Lundbeck has paused its activities in Russia due to the invasion of Ukraine, but the company will still supply medicines for as long as sanctions allow.

Thomas Borberg/Politiken/Ritzau Scanpix

Pharmaceutical firm Lundbeck is watching the war in Ukraine with concern, in addition to making sure it complies with sanctions imposed on Russia due to its invasion of its neighboring country, the leadership team says at the company’s general meeting on Wednesday.

Some of this entails clinical studies, but also medicine, which Lundbeck has decided to continue supplying to Russia – something that is allowed under the current sanctions.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs